(Gastric Cancer) Is Keytruda ± Chemotherapy Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- October 2, 2020
- Reading time: 2 minutes
On September 3, 2020, Kohei Shitara published results in JAMA Oncology from the KEYNOTE-062 Phase 3 clinical trial comparing pembrolizumab (Keytruda) monotherapy and pembrolizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in advanced gastric or gastroesophageal junction (G/GEJ) cancer patients.
The KEYNOTE-062 Phase 3 trial randomized advanced G/GEJ cancer patients (N=763) in a 1:1:1 ratio to three first-line treatment arms. Primary endpoints were PFS and OS in PD-L1-positive (CPS ≥1 and CPS ≥10) populations.
- Pembrolizumab monotherapy arm: Keytruda 200 mg every 3 weeks (N=256)
- Pembrolizumab + chemotherapy arm: Keytruda 200 mg every 3 weeks + chemotherapy (N=257)
- Placebo arm: placebo + chemotherapy (N=250)
Results at median follow-up of 29.4 months:
Overall Survival (Primary Endpoint) in PD-L1-positive (CPS ≥1): Median OS was 10.6 months (pembrolizumab monotherapy) / 12.5 months (pembrolizumab + chemotherapy) / 11.1 months (placebo). Although the pembrolizumab monotherapy arm performed better than the placebo arm, superiority was not demonstrated.
Overall Survival in PD-L1-positive (CPS ≥10): Median OS was 17.4 months (pembrolizumab monotherapy) / 12.3 months (pembrolizumab + chemotherapy) / 10.8 months (placebo). Superiority of pembrolizumab was not demonstrated.
Safety: Grade 3–5 adverse events occurred in 17% (pembrolizumab monotherapy) / 73% (pembrolizumab + chemotherapy) / 69% (placebo).
Based on the KEYNOTE-062 trial results, Kohei Shitara concluded that pembrolizumab monotherapy and pembrolizumab plus chemotherapy as first-line treatment for advanced G/GEJ cancer showed better OS than the placebo arm, with a lower incidence of adverse events in the monotherapy arm.
Source: Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer — The KEYNOTE-062 Phase 3 Randomized Clinical Trial (JAMA Oncol. 2020 Sep 3. doi:10.1001/jamaoncol.2020.3370)
- Immunotherapy
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4